MET and hepatocellular carcinoma: Another second-line agent cabozantinib, a multikinase inhibitor targeting VEGFR1-3, MET, AXL receptor tyrosine kinase, KIT, and RET, was approved by the US FDA in January 2019 for patients with HCC who have been previously treated with sorafenib.